Top

Published in:

Open Access 01-02-2008 | GENETIC EPIDEMIOLOGY

Apolipoprotein E gene is related to mortality only in normal weight individuals: The Rotterdam study

Authors: M. Carolina Pardo Silva, A. Cecile J. W. Janssens, Albert Hofman, Jacqueline C. M. Witteman, Cornelia M. van Duijn

Published in: European Journal of Epidemiology | Issue 2/2008

Abstract

Objective To investigate the relationship between the apolipoprotein E (APOE) gene and the risk of mortality in normal weight, overweight and obese individuals. Methods and Results In a population-based study of 7,983 individuals aged 55 years and older, we compared the risks of all-cause and coronary heart disease (CHD) mortality by APOE genotype, both overall and in subgroups defined by body mass index (BMI). We found significant evidence for interaction between APOE and BMI in relation to total cholesterol (p = 0.04) and HDL cholesterol (p < 0.001). Overall, APOE*2 carriers showed a decreased risk of all-cause mortality. Analyses within BMI strata showed a beneficial effect of APOE*2 only in normal weight persons (adjusted hazard ratio (HR) 0.7[95% CI 0.5–0.9]). APOE*2 was not associated with a lower risk of all-cause mortality in overweight or obese persons. The effect of APOE*2 in normal weight individuals tended to be due to the risk of CHD mortality (adjusted HR 0.5 [95% CI 0.2–1.2]). Conclusion The APOE*2 allele confers a lower risk of all-cause mortality only to normal weight individuals.

Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 2002;155:487–95.PubMedCrossRef

Horejsi B, Ceska R. Apolipoproteins and atherosclerosis. Apolipoprotein E and apolipoprotein(a) as candidate genes of premature development of atherosclerosis. Physiol Res 2000;49(Suppl 1):S63–9.PubMed

Ilveskoski E, Loimaala A, Mercuri MF, Lehtimaki T, Pasanen M, Nenonen A, Oja P, Bond MG, Koivula T, Karhunen PJ, Vuori I. Apolipoprotein E polymorphism and carotid artery intima-media thickness in a random sample of middle-aged men. Atherosclerosis 2000;153:147–53.PubMedCrossRef

Davignon J. Apolipoprotein E and atherosclerosis: beyond lipid effect. Arterioscler Thromb Vasc Biol 2005;25:267–9.PubMedCrossRef

Song Y, Stampfer MJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 2004;141:137–47.PubMed

Lee JH, Tang MX, Schupf N, Stern Y, Jacobs DM, Tycko B, Mayeux R. Mortality and apolipoprotein E in Hispanic, African-American, and Caucasian elders. Am J Med Genet 2001;103:121–7.PubMedCrossRef

Raiha I, Marniemi J, Puukka P, Toikka T, Ehnholm C, Sourander L. Effect of serum lipids, lipoproteins, and apolipoproteins on vascular and nonvascular mortality in the elderly. Arterioscler Thromb Vasc Biol 1997;17:1224–32.PubMed

Vogt MT, Cauley JA, Kuller LH. Apolipoprotein E phenotype, arterial disease, and mortality among older women: the study of osteoporotic fractures. Genet Epidemiol 1997;14:147–56.PubMedCrossRef

Stengard JH, Zerba KE, Pekkanen J, Ehnholm C, Nissinen A, Sing CF. Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men. Circulation 1995;91:265–9.PubMed

10.

Tilvis RS, Kahonen-Vare MH, Jolkkonen J, Valvanne J, Pitkala KH, Strandberg TE. Predictors of cognitive decline and mortality of aged people over a 10-year period. J Gerontol A Biol Sci Med Sci 2004;59:268–74.PubMed

11.

Hayden KM, Zandi PP, Lyketsos CG, Tschanz JT, Norton MC, Khachaturian AS, Pieper CF, Welsh-Bohmer KA, Breitner JC. Apolipoprotein E genotype and mortality: findings from the Cache County Study. J Am Geriatr Soc 2005;53:935–42.PubMedCrossRef

12.

Slooter AJ, Cruts M, Van Broeckhoven C, Hofman A, van Duijn CM. Apolipoprotein E and longevity: the Rotterdam Study. J Am Geriatr Soc 2001;49:1258–9.PubMedCrossRef

13.

Kuusisto J, Mykkanen L, Kervinen K, Kesaniemi YA, Laakso M. Apolipoprotein E4 phenotype is not an important risk factor for coronary heart disease or stroke in elderly subjects. Arterioscler Thromb Vasc Biol 1995;15:1280–6.PubMed

14.

Koivisto AM, Lempiainen P, Koivisto K, Helkala EL, Mykkanen L, Kuusisto J, Kervinen K, Kesaniemi YA, Laakso M, Soininen H. Apolipoprotein E phenotype alone does not influence survival in Alzheimer’s disease: a population-based longitudinal study. Neuroepidemiology 2000;19:327–32.PubMedCrossRef

15.

Heijmans BT, Slagboom PE, Gussekloo J, Droog S, Lagaay AM, Kluft C, Knook DL, Westendorp RG. Association of APOE epsilon2/epsilon3/epsilon4 and promoter gene variants with dementia but not cardiovascular mortality in old age. Am J Med Genet 2002;107:201–8.PubMedCrossRef

16.

Juva K, Verkkoniemi A, Viramo P, Polvikoski T, Kainulainen K, Kontula K, Sulkava R. APOE epsilon4 does not predict mortality, cognitive decline, or dementia in the oldest old. Neurology 2000;54:412–5.PubMed

17.

Skoog I, Hesse C, Aevarsson O, Landahl S, Wahlstrom J, Fredman P, Blennow K. A population study of apoE genotype at the age of 85: relation to dementia, cerebrovascular disease, and mortality. J Neurol Neurosurg Psychiatry 1998;64:37–43.PubMedCrossRef

18.

Fillenbaum GG, Burchett BM, Lee JH, Blazer DG. Mortality, apolipoprotein E in African-American, and White elders: an attempted replication. Am J Med Genet 2003;119A:141–6.CrossRefPubMed

19.

Schupf N, Costa R, Luchsinger J, Tang MX, Lee JH, Mayeux R. Relationship between plasma lipids and all-cause mortality in nondemented elderly. J Am Geriatr Soc 2005;53:219–26.PubMedCrossRef

20.

Marques-Vidal P, Bongard V, Ruidavets JB, Fauvel J, Hanaire-Broutin H, Perret B, Ferrieres J. Obesity and alcohol modulate the effect of apolipoprotein E polymorphism on lipids and insulin. Obes Res 2003;11:1200–6.PubMed

21.

Srinivasan SR, Ehnholm C, Elkasabany A, Berenson GS. Apolipoprotein E polymorphism modulates the association between obesity and dyslipidemias during young adulthood: the Bogalusa Heart Study. Metabolism 2001;50:696–702.PubMedCrossRef

22.

Boer JM, Ehnholm C, Menzel HJ, Havekes LM, Rosseneu M, O’Reilly DS, Tiret L. Interactions between lifestyle-related factors and the ApoE polymorphism on plasma lipids and apolipoproteins. The EARS Study. European Atherosclerosis Research Study. Arterioscler Thromb Vasc Biol 1997;17:1675–81.PubMed

23.

Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991;7:403–22.PubMedCrossRef

24.

Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000;894:i–xii, 1–253.

25.

1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999;17:151–83.

26.

Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26 Suppl 1:S5–20.

27.

van Gent CM, van der Voort HA, de Bruyn AM, Klein F. Cholesterol determinations. A comparative study of methods with special reference to enzymatic procedures. Clin Chim Acta 1977;75:243–51.PubMedCrossRef

28.

Executive summary of the third report of the national cholesterol education program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486–97.

29.

Slooter AJ, Houwing-Duistermaat JJ, van Harskamp F, Cruts M, Van Broeckhoven C, Breteler MM, Hofman A, Stijnen T, van Duijn CM. Apolipoprotein E genotype and progression of Alzheimer’s disease: the Rotterdam Study. J Neurol 1999;246(4):304–8.PubMedCrossRef

30.

WHO. International Statistical classification of diseases and related health problems. Geneva: World Health Organization; 1992.

31.

Cheung YB, Gao F, Khoo KS. Age at diagnosis and the choice of survival analysis methods in cancer epidemiology. J Clin Epidemiol 2003;56:38–43.PubMedCrossRef

32.

Korn EL, Graubard BI, Midthune D. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol 1997;145:72–80.PubMed

33.

Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika 1982;69:239–41.CrossRef

34.

Schachter F, Faure-Delanef L, Guenot F, Rouger H, Froguel P, Lesueur-Ginot L, Cohen D. Genetic associations with human longevity at the APOE and ACE loci. Nat Genet 1994;6:29–32.PubMedCrossRef

35.

Christensen K, Johnson TE, Vaupel JW. The quest for genetic determinants of human longevity: challenges and insights. Nat Rev Genet 2006;7:436–48.PubMedCrossRef

36.

Bathum L, Christiansen L, Jeune B, Vaupel J, McGue M, Christensen K. Apolipoprotein E genotypes: relationship to cognitive functioning, cognitive decline, and survival in nonagenarians. J Am Geriatr Soc 2006;54:654–8.PubMedCrossRef

37.

Pouliot MC, Despres JP, Moorjani S, Lupien PJ, Tremblay A, Bouchard C. Apolipoprotein E polymorphism alters the association between body fatness and plasma lipoproteins in women. J Lipid Res 1990;31:1023–9.PubMed

38.

de Beer F, Stalenhoef AF, Hoogerbrugge N, Kastelein JJ, Gevers Leuven JA, van Duijn CM, Havekes LM, Smelt AH. Expression of type III hyperlipoproteinemia in apolipoprotein E2 (Arg158 → Cys) homozygotes is associated with hyperinsulinemia. Arterioscler Thromb Vasc Biol 2002;22:294–9.PubMedCrossRef

39.

Mahley RW, Huang Y, Rall SC Jr. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J Lipid Res 1999;40:1933–49.PubMed

Title: Apolipoprotein E gene is related to mortality only in normal weight individuals: The Rotterdam study
Authors: M. Carolina Pardo Silva
A. Cecile J. W. Janssens
Albert Hofman
Jacqueline C. M. Witteman
Cornelia M. van Duijn
Publication date: 01-02-2008
Publisher: Springer Netherlands
Published in: European Journal of Epidemiology / Issue 2/2008
Print ISSN: 0393-2990
Electronic ISSN: 1573-7284
DOI: https://doi.org/10.1007/s10654-007-9202-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Apolipoprotein E gene is related to mortality only in normal weight individuals: The Rotterdam study

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2008

Comparison of allergic diseases, symptoms and respiratory infections between Finnish and Russian school children

Synergistic effect of the genetic polymorphisms of the renin–angiotensin–aldosterone system on high-altitude pulmonary edema: a study from Qinghai-Tibet altitude

Chronic obstructive pulmonary disease and mortality following hip fracture: a population-based cohort study

Inflammation a possible link between economical stress and coronary heart disease

Prior health care utilization as a potential determinant of enrollment in a 21-year prospective study, the Millennium Cohort Study

Association between number of siblings and cause-specific mortality in the Glasgow alumni cohort study